Arctoris brings together a world-class team and a revolutionary technology.

Our mission

Founded in Oxford in 2016, Arctoris is the world’s first fully automated drug discovery platform.

With millions suffering from chronic illnesses, the world continues to be in desperate need of new and better therapies to improve and extend lives. This is why we are here: we combine a world-class team with a unique set of technologies to drive our mission to revolutionize drug discovery and accelerate the development of new medicines. Better data today will lead to better drugs tomorrow.

Read more about team, technology, and your future with us below.

Our team

Our global team consists of biotech and pharma veterans, robotics and machine learning engineers, as well as seasoned life sciences executives. Together, we challenge conventions in drug discovery, and relentlessly pursue a data-first approach to find and develop new drugs faster. We are driven by our mission to revolutionize drug discovery and accelerate science.
MARTIN-IMMANUEL BITTNER

Co-founder and CEO

THOMAS A. FLEMING

Co-founder and COO

LILY ELSNER

Head of Strategy

BETH J. HOFFMAN

Advisory Board Member

DANIEL THOMAS

Head of Discovery Biology

VISHAL GULATI

Chairman of the Board

VERSHA PRAKASH

Head of Partnerships

POPPY ROWORTH

Head of Laboratory

SALLY CULLEN

Chief People Officer

SIR MICHAEL BRADY OBE

Scientific Advisor

PATRICK PICHETTE

Board Advisor

Professor Khusru Asadullah

Scientific Advisor

Stanley Lapidus

Board Advisor

Steven Holtzman

Board Advisor

Meet Ulysses

Drug discovery is a series of decision-making steps, driven by data. We developed Ulysses, a unique platform that brings together robotics, AI, and blockchain to generate data of unprecedented quality, depth and context, at scale.

With Ulysses, we enable the right decisions at the right time, reducing cycle times, decreasing attrition rates, and making drug discovery success more likely. Our platform powers our internal discovery work, and is also accessible to select partners, enabling them to accelerate their programs from idea to IND, bringing new medicines to patients faster.

Our investors

Investors logo
And a group of exceptional angels and entrepreneurs

Our values

We are always looking for our next Arctorian. At Arctoris, we value absolute integrity and trust among our team and our clients. We champion the data, focus on delivering the best-possible data quality, and always ask “how could this be done better?”. We share an obligation to dissent among a strong, mission-driven, diverse team, and we never let a team member fail.

Arctoris is growing. Come join us.

Open roles

Partnerships

Account Manager

Remote

Read more
MARTIN-IMMANUEL BITTNER

Martin-Immanuel Bittner

Co-founder and CEO

Martin completed his medical degree in Germany and his DPhil in Oncology as a Rhodes Scholar at the University of Oxford. He worked in both clinical trials and drug discovery, is a member of AACR, EACR and ESTRO, actively involved in the Open Science movement, and in 2018 was elected a member of the Young Academy of the German National Academy of Sciences in recognition of his research achievements.

THOMAS A. FLEMING

Thomas A. Fleming

Co-founder and CEO
Tom is a Royal Academy of Engineering SME Leader and was formerly a cancer researcher and Fellow of the Royal Commission of 1851 at the University of Oxford. A chemist by background, he worked both at leading CROs and pharmaceutical corporations. Tom has unique insights into drug discovery, including the critical steps from target identification & validation to high-throughput screening & lead optimisation.
LILY ELSNER

Lily Elsner

Head of Strategy

Lily met the Arctoris founding team through the inaugural cohort of Creative Destruction Lab while completing her MBA at Saïd Business School at the University of Oxford. Previously she worked in strategy and operations for the Board of Directors, and senior leadership in Card Analytics and Infrastructure at Capital One Financial Corporation, and in global M&A at Shearman & Sterling LLP in New York. She graduated from Wellesley College with a double major in Philosophy and Biological Sciences.

BETH J. HOFFMAN

Beth J. Hoffman

Advisory Board Member

Beth Hoffman PhD is a seasoned pharmaceutical and biotech executive. Beth is the CEO of San Diego-based Origami Therapeutics. During her distinguished career she has also served as Vice-President of Discovery Biology at Vertex Pharmaceuticals and held leadership positions at Amgen, Eli Lilly, and the NIH. Beth brings invaluable experience in drug
discovery and development, both from the R&D and business perspective.

DANIEL THOMAS

Daniel Thomas

Head of Discovery Biology

Dan received his BSc and PhD from the University of Leeds before joining GlaxoSmithKline, where he spent 20 years working in small molecule drug discovery directing teams in target identification and validation. At Arctoris, Dan leads the implementation of a comprehensive scientific strategy designed to deliver high-quality, reproducible and richly annotated data sets.

VISHAL GULATI

Vishal Gulati

Chairman of the Board
Vishal is an MD PhD and partner at one of Europe’s leading venture capital firms, DraperEsprit, leading their investments in the digital health and drug discovery space. He is also a board member of Horizon Discovery, Fluidic Analytics, and EcoEos. Vishal is a Rhodes Scholar and Chairman of the Digital Health Forum. Before joining DraperEsprit, Vishal worked at Atlas Ventures and the Wellcome Trust.
VERSHA PRAKASH

Versha Prakash

Head of Partnerships

Versha is the Head of Partnerships at Arctoris, where she oversees a portfolio of drug discovery partners and clients. Versha earned her PhD and completed a postdoctoral fellowship at Royal Holloway University of London, UK. Her expertise covers biotechnology and life sciences subject areas, with an emphasis on the cell and gene therapy space.

POPPY ROWORTH

Poppy Roworth

Head of Laboratory
Poppy completed her DPhil in Oncology at the University of Oxford and her BSc in Biochemistry at the University of Southampton. She worked for AstraZeneca in the Oncology iMED unit, employing robotic systems for drug discovery. Poppy also was a Visiting Researcher at OncoRay-Dresden. She actively promotes women in STEM and has won several awards as a biochemist.
SALLY CULLEN

Sally Cullen

Chief People Officer

Sally brings a wealth of knowledge and experience to Arctoris. Her passion for people and development ensures we continue to invest in our ambitious talent and culture agenda. Sally has diverse experience in building high performance teams in high growth tech companies. She has been a member of the Chartered Institute for Personnel & Development for over 20 years and is a qualified occupational psychologist.

SIR MICHAEL BRADY OBE

Sir Michael Brady OBE

Advisory Board Member

Professor Brady FRS FREng FMedSci FIET FInstP FBCS is a Professor of Information Engineering and a Professor of Oncology at the University of Oxford. He was awarded the Faraday medal and seven honorary doctorates, founded MIT’s robotics laboratory, and co-founded eight startups. He advises the board of Arctoris on technological development and strategy in biomedicine.
PATRICK PICHETTE

Patrick Pichette

Board Advisor
Patrick is a general partner at leading Canadian venture capital firm Inovia Capital, heading their London office. He is also the chairman of Twitter, board member of the Trudeau Foundation, and an active angel investor. Previously, he was Senior Vice President and CFO of Google, CFO of Bell Canada, and partner at McKinsey. He advises the board of Arctoris on its growth and financial strategy.
Professor Khusru Asadullah

Professor Khusru Asadullah

Advisory Board Member

Professor Asadullah is an expert in translational medicine and former Vice-President & Head of Target Discovery at Bayer. He spent more than 15 years as pharma executive, authored 160 publications and led the industry-changing Bayer reproducibility study. Professor Asadullah advises  the board on translational and precision medicine, data standards, and drug discovery best practices.

Stanley Lapidus

Stanley Lapidus

Advisory Board Member

Stan is a highly successful biotech and medtech entrepreneur and life sciences pioneer with over 30 granted patents. He took two companies from foundation to NASDAQ: EXACT Sciences (EXAS) and Cytyc Corporation (CYTC), bought by Hologic for $6.2 billion. Stan holds an academic appointment at MIT and advises the board on business strategy and the regulatory environment.

Steven Holtzman

Steven Holtzman

Board Advisor

Steven is an internationally recognized leader in the biopharma space. He was the CEO of Decibel Therapeutics, CEO & Founder of Infinity Pharmaceuticals, Chief Business Officer of Millennium Pharmaceuticals, and also served as EVP of Corporate Development at Biogen. Steven advises the board on business strategy, the commercial and competitive landscape, and asset-based value-generation.